Synthesis of new 4-(E)-alkenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents by Suzuki-Miyaura cross-coupling reactions

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 22, Issue 5, 2007, Pages 541-549

  Guillon, Jean ^a   Forfar, Isabelle ^a   Desplat, Vanessa ^b   Fabre, Solene Belisle ^a   Thiolat, Denis ^b   Massip, Stephane ^a   Carrie, Helene ^a   Mossalayi, Djavad ^b   Jarry, Christian ^a  

^a Laboratoire de Pharmacochimie   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

4 Alkenylpyrrolo 1,2 a quinoxaline; Antileishmanial agents; Leishmania amazonensis; Leishmania infantum; Suzuki reaction

Indexed keywords

4 ALKENYLPYRROLO[1,2 A]QUINOXALINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; CHIMANINE B; MEGLUMINE ANTIMONATE; MILTEFOSINE; PALLADIUM; PENTAMIDINE ISETHIONATE; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS COUPLING REACTION; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEISHMANIA; LEISHMANIA INFANTUM; LEISHMANIASIS; LIPOPHILICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMASTIGOTE; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; TERATOGENICITY;

ANIMALS; ANTIPARASITIC AGENTS; INHIBITORY CONCENTRATION 50; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; QUINOXALINES; TOXICITY TESTS;

LEISHMANIA AMAZONENSIS; LEISHMANIA INFANTUM;

EID: 35348984543     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701425089     Document Type: Article

References (29)

1. Croft, SL and Yardley, V. (2002) Curr Pharm Des, 8, pp. 319-342.
2. Croft, SL and Coombs, GH (2003) Trends Parasitol, 19, pp. 502-508.
3. Croft, SL, Seifert, K. and Duchene, M. (2003) Mol Biochem Parasitol, 126, pp. 165-172.
4. Singh, S. and Sivakumar, R. (2004) J Infect Chemother, 10, pp. 307-315.
5. Davis, AJ and Kedzierski, L. (2005) Curr Opin Invest Drugs, 6, pp. 163-169.
6. Ouellette, M., Drummelsmith, J. and Papadopoulou, B. (2004) Drug Resist Updates, 7, pp. 257-266.
7. Croft, SL, Barrett, M. and Urbina, J. (2005) Trends Parasitol, 21, pp. 508-512.
8. Chan-Bacab, MJ and Pena-Rodriguez, LM (2001) Nat Prod Rep, 18, pp. 674-688.
9. Fournet, A. and Munoz, V. (2002) Curr Top Med Chem, 2, pp. 1215-1237.
10. Fournet, A., Hocquemiller, R., Roblot, F., Cavé, A., Richomme, P. and Bruneton, J. (1993) J Nat Prod, 56, pp. 1547-1552.
11. Fournet, A., Ferreira, M., de Arias, A Rojas, de Ortiz, S Torres, Fuentes, S., Nakayama, H., Schinini, A. and Hocquemiller, R. (1996) Antimicrob Agents Chemother, 40, pp. 2447-2451.
12. Fournet, A., Gantier, JC, Gautheret, A., Leysalles, L., Munos, MH, Mayrargue, J., Moskowitz, H., Cavé, A. and Hocquemiller, R. (1994) J Antimicrob Chemother, 33, pp. 537-544.
13. Guillon, J., Forfar, I., Mamani-Matsuda, M., Desplat, V., Saliège, M., Thiolat, D., Massip, S., Tabourier, A., Léger, J-M, Dufaure, B., Haumont, G., Jarry, C. and Mossalayi, D. (2007) Bioorg Med Chem, 15, pp. 194-210.
14. Guillon, J., Dallemagne, P., Pfeiffer, B., Renard, P., Manechez, D., Kervran, A. and Rault, S. (1998) Eur J Med Chem, 33, pp. 293-308.
15. Guillon, J., Boulouard, M., Lisowski, V., Stiebing, S., Lelong, V., Dallemagne, P. and Rault, S. (2000) J Pharm Pharmacol, 52, pp. 1369-1375.
16. Guillon, J., Grellier, P., Labaied, M., Sonnet, P., Léger, J-M, Déprez-Poulain, R., Forfar-Bares, I., Dallemagne, P., Lemaître, N., Péhourcq, F., Rochette, J., Sergheraert, C. and Jarry, C. (2004) J Med Chem, 47, pp. 1997-2009.
17. Yoo, S. and Lee, S. (1990) Synlett, 7, pp. 419-420.
18. Kauffman, JM, Litak, PT and Boyko, WJ (1995) J Heterocyclic Chem, 32, pp. 1541-1555.
19. Zhang, Z., Tillekeratne, LMV and Hudson, RA (1996) Synthesis, 3, pp. 377-382.
20. Miyaura, N. and Suzuki, A. (1995) Chem Rev, 95, pp. 2457-2483.
21. Satoh, M., Miyaura, N. and Suzuki, A. (1986) Chem Lett, 15, pp. 1329-1332.
22. Ali, NM, McKillop, A., Mitchell, MB, Rebelo, RA and Wallbank, PJ (1992) Tetrahedron, 48, pp. 8117-8126.
23. Ciufolini, MA, Mitchell, JW and Roschangar, F. (1996) Tetrahedron Lett, 37, pp. 8281-8284.
24. Molander, GA and Rivero, M Rodriguez (2002) Org Lett, 4, pp. 107-109.
25. Molander, GA, Yun, C-S, Ribagorda, M. and Biolatto, B. (2003) J Org Chem, 68, pp. 5534-5539.
26. Molander, GA and Fumagalli, T. (2006) J Org Chem, 71, pp. 5743-5747.
27. Vouldoukis, I., Becherel, PA, Riveros-Moreno, V., Arock, M., da Silva, O., Debre, P., Mazier, D. and Mossalayi, MD (1997) Eur J Immunol, 27, pp. 860-865.
28. Vouldoukis, I., Riveros-Moreno, V., Dugas, B., Ouaaz, F., Becherel, P., Debre, P., Moncada, S. and Mossalayi, MD (1995) Proc Natl Acad Sci USA, 92, pp. 7804-7808.
29. Ferry-Dumazet, H., Garnier, O., Mamani-Matsuda, M., Vercauteren, J., Belloc, F., Billiard, C., Dupouy, M., Thiolat, D., Kolb, JP, Marit, G., Reiffers, J. and Mossalayi, MD (2002) Carcinogenesis, 23, pp. 1327-1333.